Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who received heparin (low-molecular-weight heparin [LMWH] or unfractionated heparin [UFH]) with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores. Results Out of 2,574 COVID-19 patients, 70.1% received heparin. LMWH was largely the most used formulation (99.5%). Death rates for patients receiving heparin or not were 7.4 and 14.0 per 1,000 person-days, respectively. After adjustment for propensity scores, we found a 40% lower risk of death in patients receiving heparin (hazard ratio = 0.60; 95% confidence interval: 0.49-0.74; E-value = 2.04). This association was particularly evident in patients with a higher severity of disease or strong coagulation activation. Conclusion In-hospital heparin treatment was associated with a lower mortality, particularly in severely ill COVID-19 patients and in those with strong coagulation activation. The results from randomized clinical trials are eagerly awaited to provide clear-cut recommendations.

Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study / A. Di Castelnuovo, S. Costanzo, A. Antinori, N. Berselli, L. Blandi, M. Bonaccio, R. Cauda, G. Guaraldi, L. Menicanti, M. Mennuni, G. Parruti, G. Patti, F. Santilli, C. Signorelli, A. Vergori, P. Abete, W. Ageno, A. Agodi, P. Agostoni, L. Aiello, S. Al Moghazi, R. Arboretti, M. Astuto, F. Aucella, G. Barbieri, A. Bartoloni, P. Bonfanti, F. Cacciatore, L. Caiano, L. Carrozzi, A. Cascio, A. Ciccullo, A. Cingolani, F. Cipollone, C. Colomba, C. Colombo, F. Crosta, G.B. Danzi, D. D'Ardes, K. De Gaetano Donati, F. Di Gennaro, G. Di Tano, G. D'Offizi, M. Fantoni, F.M. Fusco, I. Gentile, F. Gianfagna, E. Grandone, E. Graziani, L. Grisafi, G. Guarnieri, G. Larizza, A. Leone, G. MacCagni, F. Madaro, S. Maitan, S. Mancarella, M. Mapelli, R. Maragna, R. Marcucci, G. Maresca, S. Marongiu, C. Marotta, L. Marra, F. Mastroianni, M. Mazzitelli, A. Mengozzi, F. Menichetti, M. Meschiari, J. Milic, F. Minutolo, B. Molena, A. Montineri, C. Mussini, M. Musso, D. Niola, A. Odone, M. Olivieri, A. Palimodde, R. Parisi, E. Pasi, R. Pesavento, F. Petri, B. Pinchera, V. Poletti, C. Ravaglia, A. Rognoni, M. Rossato, M. Rossi, V. Sangiovanni, C. Sanrocco, L. Scorzolini, R. Sgariglia, P.G. Simeone, E. Taddei, C. Torti, R. Vettor, A. Vianello, M. Vinceti, A. Virano, L. Vocciante, R. De Caterina, L. Iacoviello. - In: THROMBOSIS AND HAEMOSTASIS. - ISSN 0340-6245. - 121:8(2021 Aug), pp. 1054-1065. [10.1055/a-1347-6070]

Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study

M. Mennuni;P. Agostoni;L. Aiello;G. Barbieri;P. Bonfanti;F. Cacciatore;F. Di Gennaro;M. Mapelli;R. Maragna;G. Maresca;F. Mastroianni;M. Olivieri;F. Petri;A. Vianello;
2021-08

Abstract

Introduction A hypercoagulable condition was described in patients with coronavirus disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing to disease progression and lethality. Aim We evaluated if in-hospital administration of heparin improved survival in a large cohort of Italian COVID-19 patients. Methods In a retrospective observational study, 2,574 unselected patients hospitalized in 30 clinical centers in Italy from February 19, 2020 to June 5, 2020 with laboratory-confirmed severe acute respiratory syndrome coronavirus-2 infection were analyzed. The primary endpoint in a time-to event analysis was in-hospital death, comparing patients who received heparin (low-molecular-weight heparin [LMWH] or unfractionated heparin [UFH]) with patients who did not. We used multivariable Cox proportional-hazards regression models with inverse probability for treatment weighting by propensity scores. Results Out of 2,574 COVID-19 patients, 70.1% received heparin. LMWH was largely the most used formulation (99.5%). Death rates for patients receiving heparin or not were 7.4 and 14.0 per 1,000 person-days, respectively. After adjustment for propensity scores, we found a 40% lower risk of death in patients receiving heparin (hazard ratio = 0.60; 95% confidence interval: 0.49-0.74; E-value = 2.04). This association was particularly evident in patients with a higher severity of disease or strong coagulation activation. Conclusion In-hospital heparin treatment was associated with a lower mortality, particularly in severely ill COVID-19 patients and in those with strong coagulation activation. The results from randomized clinical trials are eagerly awaited to provide clear-cut recommendations.
coagulation activation; coronavirus; COVID-19; heparin; mortality; treatments; Aged; Anticoagulants; Blood Coagulation; COVID-19; Female; Heparin; Heparin, Low-Molecular-Weight; Hospital Mortality; Humans; Italy; Male; Middle Aged; Retrospective Studies; Survival Analysis; Thrombophilia
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
gen-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
a-1347-6070.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 247.74 kB
Formato Adobe PDF
247.74 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/868429
Citazioni
  • ???jsp.display-item.citation.pmc??? 32
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 41
social impact